AAAAAA
Results: 26-39/39
Authors:
Kleiman, NS
Citation: Ns. Kleiman, A risk-benefit assessment of abciximab in angioplasty, DRUG SAFETY, 20(1), 1999, pp. 43-57
Authors:
Lincoff, AM
Califf, RM
Moliterno, DJ
Ellis, SG
Ducas, J
Kramer, JH
Kleiman, NS
Cohen, EA
Booth, JE
Sapp, SK
Cabot, CF
Topol, EJ
Citation: Am. Lincoff et al., Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors, N ENG J MED, 341(5), 1999, pp. 319-327
Authors:
McClure, MW
Berkowitz, SD
Sparapani, R
Tuttle, R
Kleiman, NS
Berdan, LG
Lincoff, AM
Deckers, J
Diaz, R
Karsch, KR
Gretler, D
Kitt, M
Simoons, M
Topol, EJ
Califf, RM
Harrington, RA
Citation: Mw. Mcclure et al., Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome - The platelet glycoprotein IIb IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience, CIRCULATION, 99(22), 1999, pp. 2892-2900
Authors:
Antman, EM
Giugliano, RP
Gibson, CM
McCabe, CH
Coussement, P
Kleiman, NS
Vahanian, A
Adgey, AAJ
Menown, I
Rupprecht, HJ
Van der Wieken, R
Ducas, J
Scherer, J
Anderson, K
Van de Werf, F
Braunwald, E
Citation: Em. Antman et al., Abciximab facilitates the rate and extent of thrombolysis - Results of thethrombolysis in myocardial infarction (TIMI) 14 trial, CIRCULATION, 99(21), 1999, pp. 2720-2732
Authors:
Lincoff, AM
Tcheng, JE
Califf, RM
Kereiakes, DJ
Kelly, TA
Timmis, GC
Kleiman, NS
Booth, JE
Balog, C
Cabot, CF
Anderson, KM
Weisman, HF
Topol, EJ
Citation: Am. Lincoff et al., Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial, CIRCULATION, 99(15), 1999, pp. 1951-1958
Authors:
Scarborough, RM
Kleiman, NS
Phillips, DR
Citation: Rm. Scarborough et al., Platelet glycoprotein IIb/IIIa antagonists - What are the relevant issues concerning their pharmacology and clinical use?, CIRCULATION, 100(4), 1999, pp. 437-444
Authors:
Marso, SP
Lincoff, AM
Ellis, SG
Bhatt, DL
Tanguay, JF
Kleiman, NS
Hammoud, T
Booth, JE
Sapp, SK
Topol, EJ
Citation: Sp. Marso et al., Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus - Results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for Stenting Trial) diabetic substudy, CIRCULATION, 100(25), 1999, pp. 2477-2484
Authors:
Spencer, WH
Lakkis, NM
Nagueh, SF
Kleiman, NS
Killip, D
He, ZX
Verani, MS
Roberts, R
Citation: Wh. Spencer et al., Transcatheter alcohol septal ablation for hypertrophic obstructive cardiomyopathy - Response, CIRCULATION, 100(11), 1999, pp. 1252-1252
Authors:
Miller, JM
Smalling, R
Ohman, EM
Bode, C
Betriu, A
Kleiman, NS
Schildcrout, JS
Bastos, E
Topol, EJ
Califf, RM
Citation: Jm. Miller et al., Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial), AM J CARD, 84(7), 1999, pp. 779-784
Authors:
Kleiman, NS
Citation: Ns. Kleiman, Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors, AM HEART J, 138(4), 1999, pp. S263-S275
Authors:
Kleiman, NS
Citation: Ns. Kleiman, Much ado about thrombin, AM HEART J, 137(2), 1999, pp. 196-198
Authors:
Kleiman, NS
Granger, CB
White, HD
Armstrong, P
Ardissino, D
Van de Werf, F
Zoldeyhi, P
Thompson, TD
Califf, RM
Topol, EJ
Citation: Ns. Kleiman et al., Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb, AM HEART J, 137(1), 1999, pp. 12-23
Authors:
Kleiman, NS
Mazur, W
Graziadei, N
Citation: Ns. Kleiman et al., Monitoring platelet aggregation, CONTEMP CAR, 2, 1999, pp. 267-285
Authors:
Kleiman, NS
Citation: Ns. Kleiman, Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists, CORON ART D, 9(9), 1998, pp. 603-616